WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004028440) VR1 ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/028440    International Application No.:    PCT/EP2003/010111
Publication Date: 08.04.2004 International Filing Date: 11.09.2003
Chapter 2 Demand Filed:    23.03.2004    
IPC:
A61K 31/17 (2006.01)
Applicants: BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE) (For All Designated States Except US).
SHIROO, Masahiro [JP/GB]; (GB) (For US Only).
YURA, Takeshi [JP/JP]; (JP) (For US Only).
YAMAMOTO, Noriyuki [JP/JP]; (JP) (For US Only).
TAJIMI, Masomi [JP/JP]; (JP) (For US Only).
TSUKIMI, Yasuhiro [JP/JP]; (JP) (For US Only)
Inventors: SHIROO, Masahiro; (GB).
YURA, Takeshi; (JP).
YAMAMOTO, Noriyuki; (JP).
TAJIMI, Masomi; (JP).
TSUKIMI, Yasuhiro; (JP)
Common
Representative:
BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE)
Priority Data:
02021367.4 24.09.2002 EP
Title (EN) VR1 ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDERS
(FR) UTILISATION D'ANTAGONISTES DU RECEPTEUR VANILLOIDE POUR LE TRAITEMENT DE TROUBLES UROLOGIQUES
Abstract: front page image
(EN)The present invention relates to methods for treating urological disorders. More particularly, this invention concerns the use of a vanilloid receptor (VR1) antagonist for the prophylaxis and treatment of urinary incontinence and overactive bladder. Such antagonists can be N-phenyl-N’-naphthyl urea derivatives or antibodies immunoreactive with VR1.
(FR)L'invention concerne des procédés de traitement de troubles urologiques. Plus particulièrement, l'invention concerne l'utilisation d'un antagoniste d'un récepteur vanilloïde (VR1) pour la prophylaxie et le traitement de l'incontinence urinaire et de l'hyperactivité de la vessie.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)